Urocortins in heart failure and ischemic heart disease

International Journal of Cardiology

Volumn 127, Issue 3, 2008, Pages 307-312

  Boonprasert, Phitsanu ^a   Lailerd, Narissara ^a,b   Chattipakorn, Nipon ^a,b,c  

^a Faculty of Medicine Chiang Mai University   (Thailand)

^b THAMMASAT UNIVERSITY   (Thailand)

^c CHIANG MAI UNIVERSITY   (Thailand)

Author keywords

Corticotropin releasing factor; CRF receptor; Heart failure; Ischemia reperfusion injury; Myocardial infarction; Urocortins

Indexed keywords

CORTICOTROPIN RELEASING FACTOR RECEPTOR; UROCORTIN I; UROCORTIN II; UROCORTIN III;

DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HEART PROTECTION; HUMAN; ISCHEMIC HEART DISEASE; KIDNEY FUNCTION; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; REPERFUSION INJURY; REVIEW;

ANIMALS; HEART FAILURE; HUMANS; MYOCARDIAL ISCHEMIA; UROCORTINS;

EID: 45849084272     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2007.11.026     Document Type: Review

References (70)

1. Minino A.M., Arias E., Kochanek K.D., Murphy S.L., and Smith B.L. Deaths: final data for 2000. Natl Vital Stat Rep 50 (2002) 1-119
2. Cowie M.R., Struthers A.D., Wood D.A., et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 350 (1997) 1349-1353
3. Mair J. Cardiac troponin I and troponin T: are enzymes still relevant as cardiac markers. Clin Chim Acta 257 (1997) 99-115
4. Rifai N., and Ridker P.M. High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease. Clin Chem 47 (2001) 403-411
5. Adams J.E., Abendschein D.R., and Jaffe A.S. Biochemical markers of myocardial injury. Is MB creatine kinase the choice for the 1990s. Circulation 88 (1993) 750-763
6. Ng L.L., Loke I.W., O'Brien R.J., Squire I.B., and Davies J.E. Plasma urocortin in human systolic heart failure. Clin Sci (Lond) 106 (2004) 383-388
7. Lewis K., Li C., Perrin M.H., et al. Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc Natl Acad Sci U S A 98 (2001) 7570-7575
8. Reyes T.M., Lewis K., Perrin M.H., et al. Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc Natl Acad Sci U S A 98 (2001) 2843-2848
9. Vaughan J., Donaldson C., Bittencourt J., et al. Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature 378 (1995) 287-292
10. Donaldson C.J., Sutton S.W., Perrin M.H., et al. Cloning and characterization of human urocortin. Endocrinology 137 (1996) 2167-2170
11. Lovenberg T.W., Liaw C.W., Grigoriadis D.E., et al. Cloning and characterization of a functionally distinct corticotropin-releasing factor receptor subtype from rat brain. Proc Natl Acad Sci U S A 92 (1995) 836-840
12. Skelton K.H., Owens M.J., and Nemeroff C.B. The neurobiology of urocortin. Regul Pept 93 (2000) 85-92
13. Baigent S.M., and Lowry P.J. mRNA expression profiles for corticotrophin-releasing factor (CRF), urocortin, CRF receptors and CRF-binding protein in peripheral rat tissues. J Mol Endocrinol 25 (2000) 43-52
14. Scarabelli T.M., Knight R., Stephanou A., et al. Clinical implications of apoptosis in ischemic myocardium. Curr Probl Cardiol 31 (2006) 181-264
15. Seres J., Bornstein S., Seres P., et al. Corticotropin-releasing hormone system in human adipose tissue. J Clin Endocrinol Metab 89 (2004) 965-970
16. Bamberger C.M., Wald M., Bamberger A.M., Ergun S., Beil F.U., and Schulte H.M. Human lymphocytes produce urocortin, but not corticotropin-releasing hormone. J Clin Endocrinol Metab 83 (1998) 708-711
17. Kimura Y., Takahashi K., Totsune K., et al. Expression of urocortin and corticotropin-releasing factor receptor subtypes in the human heart. J Clin Endocrinol Metab 87 (2002) 340-346
18. Honjo T., Inoue N., Shiraki R., et al. Endothelial urocortin has potent antioxidative properties and is upregulated by inflammatory cytokines and pitavastatin. J Vasc Res 43 (2006) 131-138
19. Kohno M., Kawahito Y., Tsubouchi Y., et al. Urocortin expression in synovium of patients with rheumatoid arthritis and osteoarthritis: relation to inflammatory activity. J Clin Endocrinol Metab 86 (2001) 4344-4352
20. Petraglia F., Florio P., Gallo R., et al. Human placenta and fetal membranes express human urocortin mRNA and peptide. J Clin Endocrinol Metab 81 (1996) 3807-3810
21. Takahashi K., Totsune K., Sone M., et al. Regional distribution of urocortin-like immunoreactivity and expression of urocortin mRNA in the human brain. Peptides 19 (1998) 643-647
22. Bittencourt J.C., Vaughan J., Arias C., Rissman R.A., Vale W.W., and Sawchenko P.E. Urocortin expression in rat brain: evidence against a pervasive relationship of urocortin-containing projections with targets bearing type 2 CRF receptors. J Comp Neurol 415 (1999) 285-312
23. Scarabelli T., and Knight R. Urocortins: take them to heart. Curr Med Chem Cardiovasc Hematol Agents 2 (2004) 335-342
24. Holmberg B.J., Morrison C.D., and Keisler D.H. Endocrine responses of ovariectomized ewes to i.c.v. infusion of urocortin. J Endocrinol 171 (2001) 517-524
25. Ikeda K., Tojo K., Sato S., et al. Urocortin, a newly identified corticotropin-releasing factor-related mammalian peptide, stimulates atrial natriuretic peptide and brain natriuretic peptide secretions from neonatal rat cardiomyocytes. Biochem Biophys Res Commun 250 (1998) 298-304
26. Parkes D.G., Vaughan J., Rivier J., Vale W.W., and May C.N. Cardiac inotropic actions of urocortin in conscious sheep. Am J Physiol 272 (1997) H2115-H2122
27. Rademaker M.T., Charles C.J., Espiner E.A., et al. Beneficial hemodynamic, endocrine, and renal effects of urocortin in experimental heart failure: comparison with normal sheep. J Am Coll Cardiol 40 (2002) 1495-1505
28. Davis M.E., Pemberton C.J., Yandle T.G., et al. Urocortin-1 infusion in normal humans. J Clin Endocrinol Metab 89 (2004) 1402-1409
29. Brar B.K., Jonassen A.K., Egorina E.M., et al. Urocortin-II and urocortin-III are cardioprotective against ischemia reperfusion injury: an essential endogenous cardioprotective role for corticotropin releasing factor receptor type 2 in the murine heart. Endocrinology 145 (2004) 24-35
30. Hsu S.Y., and Hsueh A.J. Human stresscopin and stresscopin-related peptide are selective ligands for the type 2 corticotropin-releasing hormone receptor. Nat Med 7 (2001) 605-611
31. Li C., Chen P., Vaughan J., et al. Urocortin III is expressed in pancreatic beta-cells and stimulates insulin and glucagon secretion. Endocrinology 144 (2003) 3216-3224
32. Li C., Vaughan J., Sawchenko P.E., and Vale W.W. Urocortin III-immunoreactive projections in rat brain: partial overlap with sites of type 2 corticotrophin-releasing factor receptor expression. J Neurosci 22 (2002) 991-1001
33. Takahashi K., Totsune K., Murakami O., et al. Expression of urocortin III/stresscopin in human heart and kidney. J Clin Endocrinol Metab 89 (2004) 1897-1903
34. Iino K., Sasano H., Oki Y., et al. Urocortin expression in the human central nervous system. Clin Endocrinol (Oxf) 50 (1999) 107-114
35. Chang C.P., Pearse R.V., O'Connell S., and Rosenfeld M.G. Identification of a seven transmembrane helix receptor for corticotropin-releasing factor and sauvagine in mammalian brain. Neuron 11 (1993) 1187-1195
36. Kishimoto T., Pearse R.V., Lin C.R., and Rosenfeld M.G. A sauvagine/corticotropin-releasing factor receptor expressed in heart and skeletal muscle. Proc Natl Acad Sci U S A 92 (1995) 1108-1112
37. Lovenberg T.W., Chalmers D.T., Liu C., and de Souza E.B. CRF2 alpha and CRF2 beta receptor mRNAs are differentially distributed between the rat central nervous system and peripheral tissues. Endocrinology 136 (1995) 4139-4142
38. Kostich W.A., Chen A., Sperle K., and Largent B.L. Molecular identification and analysis of a novel human corticotropin-releasing factor (CRF) receptor: the CRF2gamma receptor. Mol Endocrinol 12 (1998) 1077-1085
39. Liaw C.W., Lovenberg T.W., Barry G., Oltersdorf T., Grigoriadis D.E., and de Souza E.B. Cloning and characterization of the human corticotropin-releasing factor-2 receptor complementary deoxyribonucleic acid. Endocrinology 137 (1996) 72-77
40. Nishikimi T., Miyata A., Horio T., et al. Urocortin, a member of the corticotropin-releasing factor family, in normal and diseased heart. Am J Physiol Heart Circ Physiol 279 (2000) H3031-H3039
41. Chen R., Lewis K.A., Perrin M.H., and Vale W.W. Expression cloning of a human corticotropin-releasing-factor receptor. Proc Natl Acad Sci U S A 90 (1993) 8967-8971
42. Stenzel P., Kesterson R., Yeung W., Cone R.D., Rittenberg M.B., and Stenzel-Poore M.P. Identification of a novel murine receptor for corticotropin-releasing hormone expressed in the heart. Mol Endocrinol 9 (1995) 637-645
43. Wiley K.E., and Davenport A.P. CRF2 receptors are highly expressed in the human cardiovascular system and their cognate ligands urocortins 2 and 3 are potent vasodilators. Br J Pharmacol 143 (2004) 508-514
44. Brar B.K., Jonassen A.K., Stephanou A., et al. Urocortin protects against ischemic and reperfusion injury via a MAPK-dependent pathway. J Biol Chem 275 (2000) 8508-8514
45. Charles C.J., Rademaker M.T., and Richards A.M. Urocortins: putative role in cardiovascular disease. Curr Med Chem Cardiovasc Hematol Agents 2 (2004) 43-47
46. Terui K., Higashiyama A., Horiba N., Furukawa K.I., Motomura S., and Suda T. Coronary vasodilation and positive inotropism by urocortin in the isolated rat heart. J Endocrinol 169 (2001) 177-183
47. Rademaker M.T., Charles C.J., Espiner E.A., Frampton C.M., Lainchbury J.G., and Richards A.M. Four-day urocortin-I administration has sustained beneficial haemodynamic, hormonal, and renal effects in experimental heart failure. Eur Heart J 26 (2005) 2055-2062
48. Abdelrahman A.M., and Pang C.C. Regional haemodynamic effects of urocortin in the anaesthetized rat. Eur J Pharmacol 466 (2003) 317-321
49. Bale T.L., Picetti R., Contarino A., K oob G.F., Vale W.W., and Lee K.F. Mice deficient for both corticotropin-releasing factor receptor 1 (CRFR1) and CRFR2 have an impaired stress response and display sexually dichotomous anxiety-like behavior. J Neurosci 22 (2002) 193-199
50. Coste S.C., Kesterson R.A., Heldwein K.A., et al. Abnormal adaptations to stress and impaired cardiovascular function in mice lacking corticotropin-releasing hormone receptor-2. Nat Genet 24 (2000) 403-409
51. Gordon J.M., Dusting G.J., Woodman O.L., and Ritchie R.H. Cardioprotective action of CRF peptide urocortin against simulated ischemia in adult rat cardiomyocytes. Am J Physiol Heart Circ Physiol 284 (2003) H330-H336
52. + channels. Br J Pharmacol 135 (2002) 1467-1476
53. Latchman D.S. Urocortin protects against ischemic injury via a MAPK-dependent pathway. Trends Cardiovasc Med 11 (2001) 167-169
54. Schulman D., Latchman D.S., and Yellon D.M. Urocortin protects the heart from reperfusion injury via upregulation of p42/p44 MAPK signaling pathway. Am J Physiol Heart Circ Physiol 283 (2002) H1481-H1488
55. Yang L.Z., Kockskamper J., Heinzel F.R., et al. Urocortin II enhances contractility in rabbit ventricular myocytes via CRF(2) receptor-mediated stimulation of protein kinase A. Cardiovasc Res 69 (2006) 402-411
56. Rademaker M.T., Cameron V.A., Charles C.J., and Richards A.M. Urocortin 3: haemodynamic, hormonal, and renal effects in experimental heart failure. Eur Heart J 27 (2006) 2088-2098
57. Rademaker M.T., Cameron V.A., Charles C.J., and Richards A.M. Integrated hemodynamic, hormonal, and renal actions of urocortin 2 in normal and paced sheep: beneficial effects in heart failure. Circulation 112 (2005) 3624-3632
58. Weisinger R.S., Blair-West J.R., Burns P., et al. Cardiovascular effects of long-term central and peripheral administration of urocortin, corticotropin-releasing factor, and adrenocorticotropin in sheep. Endocrinology 145 (2004) 5598-5604
59. Mackay K.B., Stiefel T.H., Ling N., and Foster A.C. Effects of a selective agonist and antagonist of CRF2 receptors on cardiovascular function in the rat. Eur J Pharmacol 469 (2003) 111-115
60. Davis M.E., Pemberton C.J., Yandle T.G., et al. Urocortin 2 infusion in healthy humans: hemodynamic, neurohormonal, and renal responses. J Am Coll Cardiol 49 (2007) 461-471
61. Hausenloy D.J., and Yellon D.M. New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. Cardiovasc Res 61 (2004) 448-460
62. Scarabelli T.M., Pasini E., Stephanou A., et al. Urocortin promotes hemodynamic and bioenergetic recovery and improves cell survival in the isolated rat heart exposed to ischemia/reperfusion. J Am Coll Cardiol 40 (2002) 155-161
63. Brar B.K., Stephanou A., Okosi A., et al. CRH-like peptides protect cardiac myocytes from lethal ischaemic injury. Mol Cell Endocrinol 158 (1999) 55-63
64. Okosi A., Brar B.K., Chan M., et al. Expression and protective effects of urocortin in cardiac myocytes. Neuropeptides 32 (1998) 167-171
65. Brar B.K., Stephanou A., Knight R., and Latchman D.S. Activation of protein kinase B/Akt by urocortin is essential for its ability to protect cardiac cells against hypoxia/reoxygenation-induced cell death. J Mol Cell Cardiol 34 (2002) 483-492
66. Garcia-Villalon A.L., Amezquita Y.M., Monge L., et al. Mechanisms of the protective effects of urocortin on coronary endothelial function during ischemia-reperfusion in rat isolated hearts. Br J Pharmacol 145 (2005) 490-494
67. Lawrence K.M., Kabir A.M., Bellahcene M., et al. Cardioprotection mediated by urocortin is dependent on PKCepsilon activation. FASEB J 19 (2005) 831-833
68. Lawrence K.M., Townsend P.A., Davidson S.M., et al. The cardioprotective effect of urocortin during ischaemia/reperfusion involves the prevention of mitochondrial damage. Biochem Biophys Res Commun 321 (2004) 479-486
69. Liu C.N., Yang C., Liu X.Y., and Li S. In vivo protective effects of urocortin on ischemia-reperfusion injury in rat heart via free radical mechanisms. Can J Physiol Pharmacol 83 (2005) 459-465
70. Agnello D., Bertini R., Sacco S., Meazza C., Villa P., and Ghezzi P. Corticosteroid-independent inhibition of tumor necrosis factor production by the neuropeptide urocortin. Am J Physiol 275 (1998) E757-E762